Based on the Syndax Pharmaceuticals Inc stock forecast from 8 analysts, the average analyst target price for Syndax Pharmaceuticals Inc is USD 39.17 over the next 12 months. Syndax Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Syndax Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Syndax Pharmaceuticals Inc’s stock price was USD 10.81. Syndax Pharmaceuticals Inc’s stock price has changed by +20.78% over the past week, -16.33% over the past month and -46.25% over the last year.
No recent analyst target price found for Syndax Pharmaceuticals Inc
No recent average analyst rating found for Syndax Pharmaceuticals Inc
Company Overview Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York. Read Less
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (...Read More
Frequently Asked Questions About Syndax Pharmaceuticals Inc (SNDX) Stock
Based on ratings from 8 analysts Syndax Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 11 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on SNDX's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for SNDX is USD 39.17 over the next 12 months. The maximum analyst target price is USD 51 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on SNDX's stock to indicate if its overvalued.
The last closing price of SNDX's stock was USD 10.81.
The most recent market capitalization for SNDX is USD 1.18B.
Based on targets from 8 analysts, the average taret price for SNDX is projected at USD 39.17 over the next 12 months.
This means that SNDX's stock price may go up by +262.32% over the next 12 months.
We can't find any ETFs which contains Syndax Pharmaceuticals Inc's stock.
As per our most recent records Syndax Pharmaceuticals Inc has 270 Employees.
Syndax Pharmaceuticals Inc's registered address is 730 Third Avenue, New York, NY, United States, 10017.
You can get more information about it from Syndax Pharmaceuticals Inc's website at https://syndax.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Syndax Pharmaceuticals Inc (SNDX) Stock
Based on ratings from 8 analysts Syndax Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 11 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on SNDX's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for SNDX is USD 39.17 over the next 12 months. The maximum analyst target price is USD 51 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on SNDX's stock to indicate if its overvalued.
The last closing price of SNDX's stock was USD 10.81.
The most recent market capitalization for SNDX is USD 1.18B.
Based on targets from 8 analysts, the average taret price for SNDX is projected at USD 39.17 over the next 12 months.
This means that SNDX's stock price may go up by +262.32% over the next 12 months.
We can't find any ETFs which contains Syndax Pharmaceuticals Inc's stock.
As per our most recent records Syndax Pharmaceuticals Inc has 270 Employees.
Syndax Pharmaceuticals Inc's registered address is 730 Third Avenue, New York, NY, United States, 10017.
You can get more information about it from Syndax Pharmaceuticals Inc's website at https://syndax.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SNDX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
